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Abstract: Curcumin, a low molecular weight, lipophilic, major yellow natural polyphenolic, and
the most well-known plant-derived compound, is extracted from the rhizomes of the turmeric
(Curcuma longa) plant. Curcumin has been demonstrated as an effective therapeutic agent in
traditional medicine for the treatment and prevention of different diseases. It has also shown a
wide range of biological and pharmacological effects in drug delivery, and has actively been used
for the treatment of aging-associated diseases, including cardiovascular diseases, atherosclerosis,
neurodegenerative diseases, cancer, rheumatoid arthritis, ocular diseases, osteoporosis, diabetes,
hypertension, chronic kidney diseases, chronic inflammation and infection. The functional application
and therapeutic potential of curcumin in the treatment of aging-associated diseases is well
documented in the literature. This review article focuses mainly on the potential role of plant-derived
natural compounds such as curcumin, their mechanism of action and recent advances in the treatment
of aging-associated diseases. Moreover, the review briefly recaps on the recent progress made in the
preparation of nanocurcumins and their therapeutic potential in clinical research for the treatment of
aging-associated diseases.
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1. Introduction
Aging is an inevitable process for all organisms. It creates numerous cellular and molecular
malfunctions which lead to the development of various chronic diseases, also generally referred to as
aging-associated diseases. The occurrence of aging-associated diseases is increasing worldwide
and becoming the leading causes of disability and increased risk of mortality [1–3]. Some of
the most common aging-associated diseases are atherosclerosis, cancer, cardiovascular diseases,
chronic inflammation, chronic kidney diseases, diabetes, neurodegenerative diseases, hypertension,
rheumatoid arthritis, ocular diseases, osteoporosis, and infections [4,5]. Aging-associated diseases
usually develop in middle age after the prolonged exposure to an unhealthy early-life environment
involving the excessive usage of tobacco and alcohol, anxiety, lack of physical activity and the consumption
of a high-fat diet [1]. Clinical trials and epidemiological data has suggested that healthy lifestyle
interventions help to prevent many aging-associated chronic diseases, and many can even be reversed [6].
Plant-derived natural products play a vital role in the prevention and treatment of
aging-associated diseases [7]. Natural products extracted from plants has been used as an active
ingredient in traditional medicine for many centuries [8]. Some plant-derived natural products possess
a wide range of biological and pharmacological properties that have become indispensable in modern
pharmacotherapy, e.g., paclitaxel (an anticancer drug) from Taxus brevifolia, vincristine and vinblastine
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(anticancer drugs) from Catharanthus roseus, camptothecin (anticancer drug) from Camptotheca acuminata
and quercetin (anticancer drug), a polyphenol found in various vegetables and fruits [9–11]. Curcumin,
which has the chemical structure 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione,
is a natural yellow, polyphenolic pigment compound extracted from the rhizomes of turmeric
(Curcuma longa), is among these plant-derived natural products [12,13]. It is used as a food ingredient
in all forms of Indian cuisine, and it shows a wide range of pharmacological activities. It is used
for the treatment of neurodegenerative [14], atherosclerosis [15], cardiovascular [16], cancer [17],
pulmonary, autoimmune and neoplastic diseases [18], biliary and hepatic disorders [19], diabetes [20],
wound healing [21], rheumatoid arthritis [22], chronic inflammation [23], chronic kidney diseases [24],
hypertension [25], ocular diseases [26], osteoporosis [27], and skin diseases [28]. Although curcumin
possesses good therapeutic efficacy in the treatment of different diseases, the clinical administration
of curcumin is difficult due to its poor oral bioavailability, low solubility in aqueous solution,
and degradation under physiological conditions [13].
Nanocarrier-mediated delivery aids in overcoming the problems associated with curcumin and
facilitates successful delivery without affecting its therapeutic efficacy. Several carrier molecules
are used to enhance the bioavailability of curcumin such as polymeric nanoparticles (natural and
synthetic polymers), liposomes, dendrimers, solid lipid nanoparticles, and gold nanoparticles [29].
Recent research has suggested that nanoformulated curcumin has a better therapeutic index than
the native form of curcumin [30]. In this review article we primarily emphasize the therapeutic
potential of curcumin and the possible advantages of using nanocurcumin, which possesses higher
stability and increased bioavailability than free curcumin, in the prevention and treatment of
aging-associated diseases.
2. Curcumin
Turmeric, the golden spice also known as “Indian saffron” is used as a traditional medicine in
Southeast Asia [31]. The most important bioactive chemical constituents of turmeric are curcuminoids,
which include curcumin, demethoxycurcumin and bisdemethoxycurcumin [32]. Curcumin,
a hydrophobic polyphenol, is extracted from the rhizome of the herb Curcuma longa, which belongs to
the Zingiberaceae family [33]. It has a wide spectrum of biological and pharmacological activities [34].
Curcumin is less soluble in water and highly soluble in organic solvents including methanol,
ethanol, acetone and dimethyl sulfoxide [35]. Curcumin is commonly called diferuloylmethane,
and it gives a yellow color to turmeric powder. The chemical structure is shown in Figure 1a.
The ultraviolet-visible surface plasmon resonance spectrum of curcumin exhibits a strong absorption
peak between 420–430 nm. In the last 10 years, over 15,000 scientific papers have been published on
curcumin, and these numbers have been increasing annually. Scopus results for the period 2008–2017
are shown in Figure 1b.
Figure 1. (a) Chemical structure of curcumin; and (b) annual publication history of curcumin (2008–2017).
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An extensive literature survey was conducted over the last 10 years on aging-associated
diseases and their treatment strategies using the drug curcumin. Atherosclerosis-curcumin,
cancer-curcumin, cardiovascular diseases-curcumin, chronic inflammation-curcumin, chronic kidney
diseases-curcumin, diabetes-curcumin, hypertension-curcumin, neurodegenerative diseases-curcumin,
ocular diseases-curcumin, osteoporosis-curcumin, and rheumatoid arthritis-curcumin were used as
keywords to search the “Scopus” database for the period 2008–2017, and the results are represented in
Figure 2. The literature study describes the annual publication history and the recent research progress
of curcumin in relation to the above-mentioned aging-associated diseases.
Figure 2. Cont.
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Figure 2. Annual publication history (2008–2017) of curcumin with different aging-associated
diseases generated from the “Scopus” database, using the keywords (a) atherosclerosis-curcumin,
(b) cancer-curcumin; (c) cardiovascular diseases-curcumin (d) chronic inflammation-curcumin;
(e) chronic kidney diseases-curcumin; (f) diabetes-curcumin; (g) hypertension-curcumin;
(h) neurodegenerative diseases-curcumin; (i) ocular diseases-curcumin; (j) osteoporosis-curcumin; and
(k) rheumatoid arthritis-curcumin.
Biological and Pharmacological Properties of Curcumin
Currently, curcumin is being investigated as an active therapeutic agent for several types of
diseases including cardiovascular, pulmonary, skin disorders, liver disorders, fatigue, neuropathic
pain, bone and muscle loss, and anxiety, due to its well reported biological activities which include
anti-inflammatory, anti-proliferative, anti-angiogenic, pro-apoptotic, anti-oxidant, wound healing,
anti-cancer, anti-viral, and anti-diabetic effects [36–38]. It is a well-recognized plant-based drug for the
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treatment of most chronic diseases. Curcumin has exhibited excellent anti-bacterial activity against
both methicillin resistant and sensitive Staphylococcus aureus [39]. It is also one of the most frequently
prescribed drugs for the treatment of different skin diseases and skin cancer [28].
Extensive investigation has indicated that curcumin resulted in a reduction in total cholesterol
and low-density lipoprotein (LDL) levels in patients suffering from acute coronary syndrome [40],
and that it effectively reduced platelet aggregation and hyperlipidemia [41]. Curcumin possesses
anti-thrombotic activities and daily consumption helps to maintain anticoagulant status [42]. It can
promote cardiac repair and restore cardiac dysfunction [43], molecular understanding in diabetic
nephropathy [44], modulate cell cycle regulatory proteins in central nervous system-related disorders
including multiple sclerosis [45], and it can be potentially used for the treatment of hepatic diseases [46],
and different types of cancers [47]. The beneficial effects of curcumin have also been studied in detail in
ocular diseases, which include corneal diseases, eye dryness, conjunctivitis, anterior uveitis, pterygium,
regulating calcium hemostasis, cataracts and glaucoma [48].
Various in vitro and in vivo preclinical studies have demonstrated that curcumin has effective
biological pharmacological and potential clinical applications by interacting with numerous cellular
and molecular targets via a diverse range of mechanisms of action [49], which are presented in Table 1.
Table 1. Diverse range of mechanisms of action of curcumin in aging-associated diseases.
Aging-Associated Diseases Mechanism of Action References
Atherosclerosis
Reduces cholesterol accumulation; downregulates SR-A and upregulates ABCA1
by a proteasome and LXRα dependent pathway; inhibition of low density
lipoprotein oxidation; stabilization of cell membrane cholesterol.
[50–52]
Cancer
Induction of apoptotic signal; suppression of anti-apoptotic proteins; modulates
miRNAs, Wnt/β-Catenin signals, protein kinases, and proteasome activation;
inhibition of NF-κB; reverses the multidrug resistance of cancer cells.
[53]
Cardiovascular diseases
Anti-oxidant (inhibits eNOS, and iNOS); inhibits sarcoplasmic Ca2+-ATPase;
membrane stabilizing effect; prevents Adriamycin-induced cardiomyopathy;
prevents diabetic cardiovascular complications; inhibits p300 and NF-κB; decreases
serum cholesterol levels.
[16]
Chronic inflammation Alleviates oxidative stress; suppress pro-inflammatory pathways; TNF blocker. [23]
Chronic kidney diseases
Reduces inflammatory molecules MCP-1, NF-κB, TNF-α, IL-1β, COX-2 and cav-1;
induces the expression of anti-inflammatory factors such as HO-1, M6PRBP1,
and NEDD4.
[54]
Diabetes Reduces oxidative stress; reduction of blood glucose levels; stimulatesinsulin production. [55]
Hypertension Reduces AT1R mediated vasoconstriction. [25]
Neurodegenerative diseases Lowers cholesterol levels; inhibits amyloid-β; modulates microglia;Acetylcholinesterase and Tau inhibition; copper binding; anti-oxidant properties. [56]
Ocular diseases
Neuroprotection in glaucoma; anti-inflammation activities in anterior uveitis and
dry eye; anti-allergy in conjunctivitis; anti-proliferation activities and promotes
apoptosis in pterygium; inhibits neovascularization; anti-oxidative stress in
cataracts; protects epithelial barriers and promotes wound healing in
corneal diseases.
[48]
Osteoporosis Suppresses the expression of MMP-9; protective effect against bone deterioration. [57]
Rheumatoid arthritis
Anti-inflammatory activity; inhibits enzymes involved in inflammation (COX-2);
downregulates the activation of transcription factor NF-κB and expression of other
inflammatory intermediate molecules (TNF-α, adhesion molecules, MMPs, COX-2,
and 5-LOX) associated with arthritis.
[58]
ABCA1—ATP binding cassette family member 1; LXRα-Liver X receptor alpha; miRNAs—microRNAs;
eNOS—endothelial nitric oxide synthase; NF-κB-Nuclear factor kappa B; iNOS—Inducible nitric oxide
synthase; TNF—Tumor necrosis factor; MCP-1-Monocyte Chemoattractant Protein-1; IL-1β—Interleukin 1 beta;
COX-2 —Cyclooxygenase 2; cav-1—Caveolin 1; HO-1—Heme oxygenase 1; M6PRBP1-Mannose-6-phosphate
receptor binding protein 1; NEDD4-neural precursor cell expressed developmentally down-regulated protein 4;
AT1R-Angiotensin II receptor type 1; MMP-9—Matrix metallopeptidase 9; MMPs—Matrix metalloproteinase;
5-LOX—5 lipoxygenase.
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3. Therapeutic Potential of Curcumin in Aging-Associated Diseases
The aging process is related to a wide range of disorders. Aging-associated diseases are
threatening the elderly population worldwide. Research over the last few decades has studied the
therapeutic potential of curcumin and showed the beneficial aspects of curcumin in the prevention and
treatment of aging-associated diseases. The therapeutic potential of curcumin used in the treatment of
aging-associated diseases is discussed in Table 2.
Table 2. Therapeutic potential of curcumin used in the treatment of aging-associated diseases.
Aging-Associated
Diseases
Therapeutic Potential
of Curcumin
Outcomes References
Atherosclerosis
Anti-atherogenic effect of
curcumin via different
mechanisms.
The effect of curcumin was studied and compared with the drug
lovastatin, and the long-term treatment with curcumin lowered
plasma and hepatic cholesterol, and suppressed early
atherosclerotic lesions.
[59]
Cancer
Curcumin interferes with
multiple cell signaling
pathways which include cell
cycle, apoptosis, proliferation,
angiogenesis, invasion,
metastasis and inflammation.
The anticancer activity of curcumin was reported against different
cancers, and it plays a significant role in different cell signaling
pathway and numerous molecular targets. The in vitro, in vivo and
clinical studies revealed the therapeutic value of curcumin for the
treatment of “old-age“ diseases like cancer.
[60]
Cardiovascular
diseases
The inflammatory effects of
curcumin may play a key role
in the prevention of
cardiovascular diseases.
Curcumin showed the possibility of preventing atrial arrhythmias
and some ventricular arrhythmias. [16]
Chronic
inflammation
Curcumin can suppress both
acute and chronic
inflammation by scavenging
reactive oxygen species and
enhancing antioxidant
defences.
Curcumin shows very good antioxidant properties, and it plays a
key role in the prevention and treatment of chronic inflammation. [23,61]
Chronic kidney
diseases
Curcumin increases the
expression of intestinal
alkaline phosphatase and tight
junction proteins.
The study shows the potential anti-inflammatory effects of
curcumin and their positive effects for the treatment of chronic
kidney diseases.
[24]
Diabetes
Curcumin reduces glycemia
and hyperlipidemia in rodent
models, and favourably affects
some leading aspects of
diabetes which include insulin
resistance, hyperglycemia and
islet apoptosis and necrosis.
Curcumin is actively involved in the prevention and treatment of
diabetes. The study showed that curcumin and their complexes can
successfully be used for the treatment of various disorders
associated with diabetes such as liver disorders, adipose tissue
dysfunction, diabetic neuropathy, diabetic nephropathy, diabetic
vascular disease, and other complications associated with diabetes.
[20]
Hypertension
Curcumin shows beneficial
effects on hypertension; it
prevents the development of
hypertension by regulating
AT1 receptor expression.
The study was performed using curcumin in an Ang II-induced
hypertensive model, and it showed that curcumin aids in the
downregulation of the AT1 receptor in A10 cells and it subsequently
prevents hypertension.
[25]
Neurodegenerative
diseases
Curcumin has reported to be
an effective neuroprotective
agent and it may prevent
aging associated changes in
cellular proteins.
Protein homeostasis plays an important role in aging-associated
diseases. The study performed in an invertebrate model
(Caenorhabditis elegans) showed that the drug curcumin aids to
maintain protein homeostasis and increases the life span of the
model organism. Several animal model studies showed that
curcumin prevents or delays various neurodegenerative diseases.
[14]
Ocular diseases
Curcumin exhibits potential
therapeutic activity against
several ocular diseases.
Curcumin showed beneficial effects in the prevention and treatment
of several ocular diseases. The dosage of curcumin, up to 8g/day
for three months, does not produce any dose-limiting toxicity in
pharmacological studies. Clinical data proved that the few weeks of
curcumin treatment reduced the signs and symptoms of eye
discomfort and is safe in the treatment of humans.
[26]
Osteoporosis
Curcumin may be a potential
candidate for the treatment of
osteoporosis.
The protective effects of curcumin were studied against
dexamethasone induced osteoporosis in a rat model. The results
proved that curcumin effectively prevented glucocorticoid- induced
osteoporosis.
[27]
Rheumatoid arthritis
Curcumin possess various
pharmacological activities
including antiarthritic effects.
The effect of curcumin was studied in an adjuvant-induced arthritis
rat model, and it showed similar therapeutic effects for the
treatment of rheumatoid arthritis compared with the drug
methotrexate.
[22]
4. Recent Advances of Nanocurcumin in Aging-Associated Diseases
In recent years, nanotechnology-based drug delivery systems have received considerable attention
in drug delivery and pharmaceutical research due to their capability to deliver drugs and other
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substances (such as targeting ligands, fluorescent dyes) to the targeted region. Nanoformulation
offers distinct advantages in drug delivery which include lack of toxicity, high drug loading
capacity, controlled drug release, extended shelf life period, higher stability, functionalization with
specific targets, intracellular release and targeted delivery [62]. Various nano-based formulations are
successfully studied for imaging, diagnostic and therapeutic applications [63]. Recent advances in
nanotechnology have facilitated the formulation of nanocurcumin and it significantly improved the
therapeutic efficacy and bioavailability of its native counterpart [64] and provides the opportunity for
disease specific targeting [65].
Curcumin-loaded spherical polymeric nanoconstructs with lipid chains was assessed in vitro using
RAW 264.7 cells. The nanoconstructs significantly modulated the production of pro-inflammatory
cytokines without any cytotoxic effect [66]. Curcumin-conjugated magnetic nanoparticles bind with
amyloid plaques in mouse brains, which was confirmed through immunohistochemical studies and
magnetic resonance images. This study revealed the potential application of curcumin magnetic
nanoparticles to visualize amyloid plaques in Alzheimer’s disease [67]. Curcumin loaded zinc oxide
nanoparticles encapsulated with a co-polymer were successfully synthesized, and their anticancer
activity showed excellent cytotoxicity effects in AGS gastric cancer cells [68]. In vitro and in vivo studies
showed that curcumin encapsulated PLGA nanoparticles showed effective targeting and growth
inhibition of prostate cancer cells [69]. Meena et al. synthesized small positively charged curcumin
nanoparticles using PLGA as a carrier, and tested these nanoparticles in triple-negative breast cancer
cells. Nanocurcumin showed higher cellular incorporation and produced more cytotoxic effects than
free curcumin, and further apoptosis induction occurred due to DNA damage [70]. Fan et al. fabricated
curcumin loaded nanoparticles using bovine serum albumin and dextran as a carrier molecule, and
showed improved cellular antioxidant activity in Caco-2 cells [71]. Curcumin loaded solid lipid
nanoparticles were synthesized and were revealed as a safe and effective therapeutic agent for the
treatment of lipopolysaccharide-induced sepsis in IL-1b transgenic mice [72]. Curcumin nanoparticles
possessed cardio protection against palmitate induced cardiomyocyte apoptosis in H9C2 embryonic rat
heart-derived cells, and may be an alternative treatment for lipid toxicity and myocardial injury [73].
Dewangan et al. prepared curcumin-carboxymethyl cellulose acetate butyrate nanoparticles in the
size range of 166.5 ± 4.2 nm with higher loading efficiency. This study demonstrated superior
anti-inflammatory effects without any specific side effects for the successful treatment on adjuvant
induced arthritis in rats [74]. The curcumin encapsulated PLGA nanoparticle approach enhanced the
effect of curcumin against bone loss. It showed significant beneficial effects on osteoporotic bone loss
treatment with an improved therapeutic index [75]. Curcumin encapsulation was performed using a
novel nanomicelle formulation which significantly improved in vitro cellular uptake and in vivo corneal
permeation as compared to free curcumin [76]. Some to the recent advances in the preparation of
nanocurcumin for the treatment of aging-associated diseases are well studied and are listed in Table 3.
Table 3. Recent advances in the preparation of nanocurcumin for the treatment of
aging-associated diseases.
Aging-Associated
Diseases Detail of Nanoparticles Size (nm) Outcomes References
Cancer
Curcumin loaded cationic
liposome- polyethylene glycol
(PEG) and poly (ethylene
imine) complex
270 nm
Curcumin liposomes showed five-fold cytotoxic activity
on curcumin-sensitive cells and twenty-fold against
curcumin-resistant cells compared to native curcumin,
and achieved 45 ± 0.2% curcumin encapsulation
efficiency in the liposome complex. In vivo studies
showed that the administration of curcumin liposomes
inhibited 60–90% of tumor growth.
[77]
Cancer Curcumin loaded silk fibroinnanoparticles 155–170 nm
Curcumin loaded silk fibroin nanoparticles were
synthesized using both physical adsorption (drug
loading content of 6.63 ± 0.09% and encapsulation
efficiency of 53.75 ± 0.81%) and co-precipitation (drug
loading content of 2.47 ± 0.11% and encapsulation
efficiency of 48.84 ± 2.67%). The synthesized material
showed excellent antitumor activity against both Hep3B
and Kelly cells.
[78]
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Table 3. Cont.
Aging-Associated
Diseases Detail of Nanoparticles Size (nm) Outcomes References
Cardiovascular
diseases
Colloidal nanoparticles
(Curcumin with gum ghatti
solution)
190 nm
A small amount of synthesized colloidal curcumin
nanoparticles could be more therapeutically effective for
heart failure than native curcumin.
[79]
Chronic
inflammation
Nano-emulsified curcumin
(NEC) -
NEC was orally supplied to NZM2410 mice (lupus
nephritis model) and kidney function was monitored by
testing blood urea nitrogen. Results suggested that NEC
has a good therapeutic potential in the treatment of
chronic inflammation and other autoimmune diseases.
[80]
Chronic kidney
diseases Curcumin nanoparticles 80–100 nm
The in vitro and in vivo study suggested that the
curcumin nanoparticles enhanced the treatment efficacy
of Rhabdomyolysis induced acute kidney injury than
free curcumin. The release study was performed using
dialysis. The initial 20 h of dialysis showed that upto
40% of curcumin nanoparticles were released and 80% of
free curcumin was released. Nanoparticulate curcumin
achieved prolonged release profile than free curcumin.
[81]
Neurodegenerative
diseases
Nanocurcumin (Curcumin
loaded p(PEG-poly-lactic acid)
micelles
80 nm
There was improved bioavailability of nanocurcumin in
the brains of Tg2576 mice as compared to free curcumin,
and nanocurcumin showed positive effects in the
treatment of Alzheimer’s disease. The entrapment
efficiency of curcumin was almost 100% and the loading
efficiency of curcumin was 37.6%.
[82]
Ocular diseases Curcumin encapsulated PLGAnanoparticles 282.50 ± 5.72 nm
The study demonstrated the potential of curcumin
encapsulated nanoparticles in managing diabetic
cataracts in a streptozotocin induced diabetic rat cataract
model. The enhanced performance of nanocurcumin
was observed in different biochemical pathways than
free curcumin. It may be due to the improved oral
bioavailability of curcumin.
[83]
Osteoporosis
Gold nanoparticles
functionalized with
cyclodextrin curcumin
complexes
36.3 nm
Loading efficiency of curcumin was around 38.95% and
the curcumin loaded nanoparticle complex showed an
effective intracellular uptake and acts as a potential
therapeutic agent in the treatment of bone diseases
associated with excessive bone resorption.
[84]
Rheumatoid
arthritis
Curcumin nanoemulsion
(curcumin, solutol-HS 15,
soybean oil)
150 nm
In vivo rat study showed that the synthesized curcumin
nanoemulsion acts as an effective antiarthritic agent.
The oral route of curcumin nanoemulsion showed
threefold increase of AUC (area under the curve) and
Cmax value than the suspension (intravenous (iv) route)
and it significantly enhanced the drug absorption than
free curcumin. Overall, the in vivo rat study suggested
that the nanoform of curcumin aids to convert the
therapy route from iv to oral administration for the
effective treatment of RA therapy
[22]
5. Clinical Application of Curcumin in Aging-Associated Diseases
Curcumin has been extensively used in clinical trials and is showing positive outcomes for the
treatment of aging-associated diseases. The global market is predominantly focused on curcumin
as a health supplement due to its effective antioxidant and anti-inflammatory properties [39].
The different aging-associated diseases along with curcumin were used as a keyword to search
the “https://clinicaltrials.gov” database. The number of clinical trials are listed in Table 4 and some
of the major global clinical trial status of curcumin in aging-associated diseases are listed in Table 5.
Table 4. Number of clinical trials generated from the “https://clinicaltrials.gov” database using the
keywords (curcumin and the different aging-associated diseases).
Keywords Used No. of Studies Found
Atherosclerosis-curcumin 1
Cancer-curcumin 57
Cardiovascular diseases-curcumin 9
Chronic inflammation-curcumin 2
Chronic kidney diseases-curcumin 5
Diabetes-curcumin 11
Hypertension-curcumin 1
Neurodegenerative diseases-curcumin 6
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Table 4. Cont.
Keywords Used No. of Studies Found
Ocular diseases-curcumin 4
Osteoporosis-curcumin 0
Rheumatoid arthritis-curcumin 2
Table 5. Status of some of the major global clinical trials of curcumin in aging-associated diseases.
ClinicalTrials.gov
Identifier Ages (Years) Disease Doses of Curcumin Phase Reference
NCT02998918 18 to 60 (Adult)
Inflammation
Atherosclerosis
Cardiovascular Disease
500 mg of curcumin phytosome
twice daily for 1 week 2 [85]
NCT00973869 18 and older(Adult, Senior) Colorectal cancer
Oral curcumin once daily for
14–28 days 1 [86]
NCT02099890 18 and older(Adult, Senior)
Neuropathic pain;
Depression;
Cognitive impairment;
Somatic neuropathy;
Autonomic dysfunction
InflanNox capsule (400 mg
curcumin) taken 3 times daily
along with other
anti-inflammatory supplements
3 [87]
NCT02369549 18 and older(Adult, Senior) Chronic kidney disease
Three 30 mg capsules of
micro-particle curcumin daily in
the morning
3 [88]
NCT02529969 40 to 65 (Adult) Non-insulin dependentdiabetes 500 mg curcumin capsule 2 [89]
NCT02984813 18 and older(Adult, Senior)
Open-angle glaucoma
diabetic retinopathy
Two pills daily (one contains
curcumin and other contains
active compounds) for 3 months
1 [90]
NCT00164749 50 and older(Adult, Senior) Alzheimer’s disease
Two different dosages (1 g/day
and 4 g/day) along with ginkgo
extract
2 [91]
NCT00752154 18 and older(Adult, Senior) Rheumatoid arthritis
Curcumin (Longvida™) 4
capsules approximately 2 g/day
for 2 weeks, then the dose will be
increased to 4 capsules twice a
day (4 g/day)
Early
phase 1 [92]
6. Future Perspectives and Conclusions
In this review, we discussed in some detail the therapeutic potential of curcumin for the prevention
and treatment of aging-associated diseases. Curcumin is a well-known plant-derived compound
that exhibits a wide range of biological and pharmacological effects in modern medicine. It is
well documented in the literature and shows positive effects on the treatment of aging-associated
diseases. However, despite the fact that the native form of curcumin possesses good therapeutic
efficacy, the clinical administration is problematic due to their poor oral bioavailability and stability.
Recent advances in nanotechnology have helped to overcome these difficulties and efficiently deliver
curcumin to the targeted region thereby improving curcumin bioavailability. An extensive literature
study strongly suggests that the nanocarrier-mediated delivery of curcumin will become a successful
treatment strategy for aging-associated diseases. Moreover, future perspectives should include
additional clinical trial investigations on the formulation of nanocurcumin with improved stability
and oral bioavailability, and focus more on targeted drug delivery of curcumin for the treatment of
aging-associated diseases.
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